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Centralization  of  the  management  of
sarcoma?  Probably  yes,  but  not  only  for
surgical  practice
There  is  probably  a  need  to  concentrate  and  centralize  the  management  of  sarcoma,  at
least,  that  is  the  message  published  by  Charles  Honoré  and  collaborators  in  this  issue  of
Journal  of  Visceral  Surgery  [1].  Sarcoma  and  related  malignant  diseases  are  beginning  to
be  better  understood  and  above  all,  identiﬁed.  Within  the  broad  category  of  ‘‘sarcoma’’,
there  are  more  than  a  hundred  different  mutations  and  distinct  genomic  proﬁles,  making
it  difﬁcult  to  remain  informed  and  therefore  competent  without  some  form  of  specializa-
tion.  It  is  important  to  know  the  different  therapeutic  strategies  speciﬁc  to  each  type  of
sarcoma.  Here,  the  message  of  the  authors  is  clear  and  coherent;  radiologic,  clinical  and
biological  analysis  should  be  performed  in  one  of  the  centers  of  the  Network.  The  fact
that  non-expert  pathologists  can  make  mistakes  and  confuse  benign  tumors  and  malignant
sarcoma  in  up  to  8%  of  cases  is  excusable.  But,  pathologists  have  opted  for  a  different  way
to  deal  with  sarcoma,  that  of  improving  training,  and  encouraging  collaboration  between
pathologists  by  exchanging  their  virtual  slides  for  double  reading  rather  than  relying  on
centralization.
According  to  the  authors,  any  patient  with  an  unexplained  soft  tissue  mass  (>  5  cm
if  superﬁcial,  or  of  any  size  if  deep)  should  be  referred  to  a  center  that  can  provide  a
multidisciplinary  approach  to  management,  i.e.  a  center  belonging  to  the  NetSarc  network.
The  deﬁnition  of  the  multidisciplinary  approach  of  the  authors  is  a  bit  restrictive.  What
would  happen  if  these  recommendations  were  put  into  action?
In  a  Swedish  study  where  criteria  similar  to  the  5  cm  limit  proposed  by  the  authors  were
applied,  the  activity  of  the  reference  centers  increased.  Four  patients  were  seen  for  each
patient  diagnosed  with  sarcoma,  with  the  other  three  having  benign  disease  [2].  Given
the  delays  required  to  set  up  a  complex  management  plan  in  certain  oncology  centers,
or  to  ﬁnd  a  spot  in  the  operating  schedule,  do  we  not  run  the  risk  of  overloading  existing
organizations  and  creating  inefﬁcient  coverage?  Would  it  not  be  better  to  privilege  an
organization  based  on  transferring  patient  ﬁles  for  close  scrutiny,  with  referral  only  for
highly  pre-selected  patients?  This  is  the  system  that  prevails  in  Oslo,  in  the  sole  oncologic
center  in  all  of  Norway.  Certainly,  in  Norway,  the  infrastructure  necessary  for  discussion
of  patient  records  in  the  care  framework  is  real  and  works  well.
http://dx.doi.org/10.1016/j.jviscsurg.2015.07.004
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The  French  surgical  protagonists  are  persuaded  that  cen-
ralization,  performed  as  early  as  possible  in  the  diagnostic
pproach  of  sarcomas,  should  help  to  avoid  irreparable  mis-
akes,  such  as  incomplete  excision  or  tumor  fragmentation,
nd  is  therefore  imperative.  They  do  have  arguments,  not
xposed  in  the  article  by  C.  Honoré  et  al.  because  they  are
ebatable  on  a  scientiﬁc  level,  but  they  do  exist.  These
rguments  for  nationwide  accreditation  are  discussed  by
he  National  Institute  of  Cancer,  and  since  it  was  decided
 few  years  ago  that  only  centers  that  operated  on  more
han  30  patients  with  gastrointestinal,  urologic,  or  breast
ancer  would  be  accredited,  the  question  of  operation  for
arcoma  arises  as  well.  Obviously,  sarcomas,  being  of  mes-
nchymal  origin,  are  not  related  to  a  particular  organ,  an
rgument  that  changes  the  initially  described  logic.  In  many
ases,  the  diagnosis  of  sarcoma  is  only  made  postoperatively,
s  occurs  often  in  pancreatic  sarcoma,  where  clinical  pre-
entation  is  unusual,  and  diagnosis  is  conﬁrmed  only  after
ultiple  molecular  analyses,  that  are  impossible  to  per-
orm  preoperatively  [3].  Should  surgery  for  uterine  sarcoma
e  performed  by  a  gynecologic  surgeon,  a  surgeon  special-
zed  in  sarcoma  or  a  gastrointestinal  surgeon?  Should  pelvic
arcoma  be  managed  by  a  surgeon  capable  of  performing
erineal  reconstruction  or  by  a  surgeon  specialized  in  can-
er  but  who  is  not  familiar  with  all  the  possible  techniques
sed  for  complex  pelvic  tumors  [4]? At  best,  several  sur-
eons  should  be  available  to  participate  simultaneously  in
he  surgery,  but  this  sort  of  organization  is  often  too  com-
lex.  The  statistics  of  the  centers  in  the  NetSarc  network
re  available.  In  2014,  the  results  of  procedures  performed
y  one  of  the  designated  competent  teams  belonging  to  the
arcoma  group,  showed  that  58%  of  their  resections  were
0,  while  34%  of  resections  were  R1  or  R2.  The  R0  vs.  R1  or
2  resections  performed  outside  the  Network  centers  were
8%  and  55%,  respectively.  Given  that  survival  is  directly
elated  to  the  completeness  of  excision,  this  is  important
o  consider.
But,  caution  is  warranted  concerning  studies  based  solely
n  practice.  Indeed,  what  physician  is  likely  to  refer  a 75-
ear-old  patient  with  locally  advanced  sarcoma  who  lives
our  hours  away  from  the  specialized  center  for  management
f  a  tumor  that  would,  in  any  case,  be  imperfect,  because
he  tumor  was  not  resectable  in  totality?  Probably  no  one.
ut,  the  difference  in  R0  resection  rates  is  probably  not  only
ue  to  this  bias,  but  also  to  the  better  quality  of  overall
are.  Still,  this  must  be  proven,  because  changing  the  entire
rganization  of  our  care  modalities  incurs  costs  that  have
o  be  justiﬁed,  an  ongoing  problem  in  Europe  for  the  last
0  years  [5].
Should  the  change  only  concern  those  surgeons  special-
zed  in  sarcomas?  If  one  reads  a  magazine  article  describing
he  best  institutions  for  management  of  patients  with  bone
umors  (e.g.  ‘‘Le  Point’’  in  France),  the  activity  in  the  20
ighest  ranking  centers  ranged  from  90  to  22  cases  per  year
median  40  cases  per  year).  With  such  limited  numbers,  cen-
ralization  in  this  case  does  seem  possible.  Is  this  a  useful
nd  realistic  goal  for  GIST  tumors?  Of  note,  the  Internet
ite  of  one  of  the  oncology  centers  states  unequivocally
hat  ‘‘Surgery  is  the  key  to  treatment.  It  should  be  per-
ormed  after  multidisciplinary  review  by  the  entire  team
radiologists,  pathologists,  surgeon,  medical  oncologist  and
adiotherapist).  Surgery  should  be  performed  by  a  surgeon
pecialized  in  management  of  soft  tissue  or  bone  sarcoma,
r  of  GIST,  because  the  surgical  rules  of  treatment  are  well
eﬁned,  and  their  observance  sets  the  scene  for  the  risk
f  recurrence.’’  In  other  words,  surgery  performed  by  a
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on-specialist  increases  the  risk  of  recurrence.  This  is  the
essage  proposed  by  the  authors  of  the  article  published  in
he  Journal  of  Visceral  Surgery  [1].
Nonetheless,  we  know  that  practice  is  more  complex  than
hat.  Expert  surgeons  do  not  have  the  same  outcomes  when
perating  in  inexperienced  centers  as  when  they  operate  in
edicated  centers.  This  is  what  happened  to  the  Japanese
urgeon  who  participated  in  the  Dutch  stomach  cancer  study
 few  years  ago  [6].  The  death  rate  in  inexperienced  centers
as  so  high  that  the  results  favored  D1  lymphadenectomy.
ortunately,  long-term  analysis  of  this  same  study  showed
hat  survival  was  increased  with  extended  lymphadenec-
omy  [6].  One  surgeon  alone,  however  brilliant,  is  only  as
ood  as  his  surroundings,  the  team  and  his  collaborators.
e  all  know  that,  so  why  not  validate  centers,  and  not  the
urgeons?  The  authors  state  that  centralization  of  mana-
ement  of  sarcoma  in  France  has  been  validated  in  three
ational  centers.  But,  since  the  writing  of  this  article,  one
f  the  authors  has  left  one  of  these  centers:  does  this  mean
hat  there  will  now  be  four  leading  centers?  As  I  recall,  Cer-
erus,  the  watchdog  of  the  Gates  of  Hell  had  only  three
eads.
It  has  been  widely  taught  that  surgery  for  sarcoma
as  the  particularity  that  resection  should  be  guided  by
natomic  structures  or  compartments  since  they  are  con-
idered  as  robust  barriers  capable  of  containing  disease.
his  type  of  surgery  has  been  extensively  studied  for  both
orso  and  extremity  sarcomas.  Compartmental  excision  in
xtremities  results  in  major  functional  sequelae  and  is  no
onger  considered  standard  therapy  today.  Pre-  or  post-
reatment  therapy,  whether  by  curietherapy,  radiotherapy
r  isolated  extremity  chemoperfusion,  is  very  often  pro-
osed  to  decease  the  size  of  the  lesions  prior  to  surgery.
Certain  colleagues,  who  are  involved  in  the  management
f  retroperitoneal  and  abdominal  sarcomas,  recommend
hat  excision  should  be  wide  [7].  Why  therefore  retain
he  concept  of  extra-compartmental  excision  for  abdomino-
elvic  surgery?  Because  retrospective  studies  seem  to
ndicate  that  outcome  is  better  when  adjacent  organs  are
xcised,  even  when  they  are  not  involved?  Nonetheless,  as
nderscored  recently  by  a  surgeon  of  the  Sloan  Kettering
ancer  Center  in  New  York,  more  than  half  of  patients  with
etroperitoneal  leiomyosarcoma  will  have  systemic  recur-
ence  after  wide  exenterative  resection,  despite  only  a  5%
ncidence  of  local  recurrence  [8].  This  cannot,  however,  jus-
ify  maximalistic  surgery  that  drastically  impairs  the  quality
f  life  and  seems  overly  aggressive.  The  large  collected
eries  reported  by  the  French  Association  for  Surgery  a  few
ears  ago  found  no  advantage  to  wide  excisional  surgery,
ven  when  en  bloc  resection  of  the  kidney  and  colon  along
ith  the  primary  tumor  was  easy  to  perform.
Thus,  we  must  ask  whether  there  is  a  need  to  central-
ze  surgery  for  gastric  GIST  tumors  when  most  radiologist
r  endoscopists  can  make  the  correct  diagnosis  preop-
ratively  and  most  gastrointestinal  surgeons  can  perform
artial  gastrectomy  via  laparoscopy?  I am  not  convinced.
or  a  voluminous  vena  cava  sarcoma,  there  is  no  doubt
hat  prognosis  would  be  much  better  if  the  patient  under-
ent  surgery  in  a  high  volume  center  rather  than  in  a
ow  volume  center  or  were  not  operated  at  all.  Since
he  involved  part  of  the  vena  cava  is  often  infra-renal,
enous  reconstruction  is  not  necessary.  But,  yes,  we  agree
hat  for  the  other  sarcomas,  centralized  management  and
ata  collection  to  better  understand  the  molecular  proﬁles
ill  help  avoid  useless  compartmental  maximalist  opera-
ions.
Editorial  
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